Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes

Post-transplant lymphoproliferative disease (PTLD) represents a serious complication following allogeneic hematopoietic stem cell transplantation (alloHSCT). Previously, survival rates of PTLD have improved due to the introduction of rituximab. However, reports on curative management of refractory P...

Descripción completa

Detalles Bibliográficos
Autores principales: Mika, Thomas, Strate, Katharina, Ladigan, Swetlana, Aigner, Clemens, Schlegel, Uwe, Tischoff, Iris, Tischer-Zimmermann, Sabine, Eiz-Vesper, Britta, Maecker-Kolhoff, Britta, Schroers, Roland
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930172/
https://www.ncbi.nlm.nih.gov/pubmed/31921871
http://dx.doi.org/10.3389/fmed.2019.00295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930172/
https://www.ncbi.nlm.nih.gov/pubmed/31921871
http://dx.doi.org/10.3389/fmed.2019.00295

Ejemplares similares